Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir + TD-6450 + Ribavirin in HCV Genotype 4
NCT02593162Phase 2Completed
- Sponsor
- Trek Therapeutics
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TD-6450 in hepatitis C (HCV), sponsored by Trek Therapeutics. Started Oct 2015; status: completed.
02
Drugs
TD-6450
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02593162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593162.